Krak - Opdag nærheden - Søg lokalt.

København, 18/09/2025 - 15:46

PRM / LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)

The first late-breaking presentation was the phase 3 trial results for DELTA TEEN, showing delgocitinib cream had superior efficacy compared to cream vehicle and was generally well tolerated in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1   In a second late-breaking presentation, pooled data from five phase 2b and phase 3 trials of delgocitinib cream confirmed a consistent safety profile for the treatment of moderate to severe CHE in adults.2  Fifteen other pieces of delgocitinib cream research formed part of LEO Pharma’s most ambitious scientific program to date at EADV 2025.3-17

Rettigheder kontakt afsender

Af: Via Ritzau

Pressemeddelelse fra LEO Pharma

BALLERUP, Denmark, 18 September 2025 – LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking delgocitinib cream presentations for Chronic Hand Eczema (CHE), showcasing the findings for the DELTA TEEN phase 3 trial and the pooled safety data from five phase 2b and phase 3 trials.1,2 Fifteen additional abstracts were also presented as part of LEO Pharma’s extensive scientific program at the 34th European Academy of Dermatology and Venereology (EADV) Congress in Paris.3-17

The 16-week DELTA TEEN phase 3 clinical trial (N=98) assessed the efficacy and safety of delgocitinib cream in adolescents, aged 12-17, with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate. The study met the primary endpoint as assessed by the Investigator’s Global Assessment for CHE Treatment Success (IGA CHE TS) at Week 16, defined as an IGA-CHE score of 0/1 (clear/almost clear) with a =2 step improvement from baseline. Delgocitinib cream was shown to be superior in comparison to cream vehicle, with 63.5% of patients responding in the delgocitinib cream arm vs. 29.2% in the cream vehicle arm.1

The delgocitinib cream treatment also showed superiority to cream vehicle across key secondary outcome measures. This included a =90% improvement in the Hand Eczema Severity Index (HECSI-90) score from baseline to Week 16 (71.6%) compared to cream vehicle (37.5%) and a =4-point reduction in Hand Eczema Symptom Diary (HESD) itch (64.8% vs. 36.8%), pain (63.3% vs. 33.3%), and total (55.6% vs. 31.3%) scores from baseline to Week 16.1 

No serious adverse events (AEs) were reported, and all AEs reported with delgocitinib cream were mild or moderate in severity. The overall proportion of patients reporting AEs was slightly higher for delgocitinib cream than for cream vehicle. Few AEs assessed as probably or possibly related to the trial drug and AEs leading to withdrawal from the trial or permanent discontinuation were reported, with numerically lower rates for delgocitinib cream than cream vehicle.1

Delgocitinib is not approved for use in patients aged 12-17 years, and the efficacy and safety in this population has not been evaluated by any health authority.

“The findings from the phase 3 DELTA TEEN trial may offer hope for young people whose CHE can impact their wellbeing and leisure activities,” said Professor Sonja Molin, Academic Dermatologist at Charite Universitätsmedizin Berlin and Adjunct Associate Professor of Dermatology at Queen’s University and coordinating investigator. “These results are encouraging and bring us one step closer to advancing the standard of care for this underserved patient group, helping to fulfill their unmet dermatological needs.”

In addition, results from a pooled analysis of five phase 2b and phase 3 trials were unveiled as the company’s second late-breaking presentation for CHE at EADV 2025.2 The analysis assessed the short- and long-term safety profiles of delgocitinib cream for the treatment of CHE for up to 52 weeks.2  

The data integrated five trials and analyzed the safety profile of delgocitinib cream compared to cream vehicle and oral alitretinoin.2 The findings demonstrated that during the initial treatment period (ITP), the event rates (R) of AEs with delgocitinib cream (R=302.1) were similar to cream vehicle (R=337.5) and notably lower than oral alitretinoin (R=830.2).2 It was also found that the safety profile of delgocitinib cream during the as-needed treatment period remained consistent with the ITP, with AE rates decreasing in frequency over time.2 The pooled safety data support the wider safety profile of delgocitinib cream for up to 52 weeks of treatment in adults with CHE.2

“The results from the pooled safety analysis are incredibly valuable as they further strengthen our understanding of this treatment option,” said Dr. Robert Bissonnette, Lead Author and MD from Innovaderm Research, Montreal. “It is reassuring to see that the safety data pooled from five clinical trials remains consistent with previously established findings.”

“We remain deeply committed to further raising awareness of CHE and expanding our extensive scientific research, not only to advance medical dermatology, but, most importantly, to support those living with this debilitating condition,” said Professor Jacob Pontoppidan Thyssen, Chief Scientific Officer & Executive Vice President, Science, Search & Innovation at LEO Pharma. “Nearly half of CHE patients feel they are a burden to their families, and around 63% avoid holding hands with their partners, highlighting the profound everyday impact this disease can have on patients’ lives. These figures are more than just statistics; they reflect the real and often unseen challenges faced by those living with CHE. At LEO Pharma, we are dedicated to reducing the burden of this skin condition, which we acknowledge affects far more than just the skin.”

*ENDS*

About the DELTA TEEN Trial

DELTA TEEN was a 16-week, phase 3, randomized, double-blind, vehicle-controlled, parallel group, multi-site trial to evaluate the efficacy and safety of twice-daily applications of delgocitinib cream compared with cream vehicle in adolescents 12-17 years of age with moderate to severe CHE.18

The primary endpoint of DELTA TEEN was the Investigator’s Global Assessment for chronic hand eczema Treatment Success (IGA-CHE TS) at Week 16. Treatment Success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline.18

About the Phase 2b Dose-ranging Trial

The phase 2b Dose-ranging Trial was a 16-week, phase 2b, double-blind, randomized, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice-daily application of delgocitinib cream 1, 3, 8, and 20 mg/g for 16 weeks in adult subjects with mild to severe CHE.19

The primary endpoint of the trial was the Investigator’s Global Assessment for chronic hand eczema Treatment Success (IGA-CHE TS) at Week 16. Treatment Success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline.19

About the DELTA 1, 2 and 3 Trials

The primary objective for the randomized, double-blind, vehicle-controlled, multi-center phase 3 clinical trials (DELTA 1 and DELTA 2) was to evaluate the efficacy of twice-daily applications of delgocitinib cream compared with cream vehicle in the treatment of adults with moderate to severe CHE.20-22

The primary endpoint of the trials was the Investigator’s Global Assessment for chronic hand eczema Treatment Success (IGA-CHE TS) at Week 16. Treatment Success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline. Additional IGA-CHE scores included 2 (mild), 3 (moderate), and 4 (severe).20-22

Key secondary endpoints at Week 16 included reduction of itch and pain scores of =4 points measured by the Hand Eczema Symptom Diary (HESD) from baseline to Week 16, as well as at least 75% improvement from baseline and at least 90% improvement from baseline on the Hand Eczema Severity Index (HECSI) at Week 16. The number of treatment-emergent adverse events from baseline to Week 16 defined the key safety endpoint of the trials.20-22

Subjects who completed 16 weeks of treatment with delgocitinib cream or cream vehicle twice daily in trials DELTA 1 or DELTA 2 were offered to roll-over to the 36-week DELTA 3 Open-label, Multi-site Extension trial. The purpose of this extension trial was to evaluate the long-term safety of delgocitinib.23

About the DELTA FORCE Trial

DELTA FORCE was a 24-week, randomized, assessor-blinded, active-controlled, parallel-group, phase 3, two-arm trial to compare the efficacy and safety of delgocitinib cream twice-daily with oral alitretinoin capsules once-daily in adult participants with severe chronic hand eczema.24

The primary endpoint of the trial was the change in Hand Eczema Severity Index (HECSI) score from baseline to Week 12. Participants assigned to receive delgocitinib cream applied the drug to the skin twice a day for 16 weeks. Participants assigned to receive alitretinoin capsules took the drug orally once a day for 12 weeks. All participants were permitted to continue for up to 24 weeks if the doctor considered that they were benefiting from the treatment.24

About Chronic Hand Eczema

Chronic Hand Eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.25,26 CHE is one of the most common skin diseases of the hands with a global prevalence rate of approximately 4.7%.27,28 In a substantial number of patients, HE can develop into a chronic disease.27 CHE is a fluctuating disease characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.29

CHE has been shown to cause psychological and functional burdens that impact patient quality of life,30,31 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the condition.32 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.33

About ANZUPGO® (delgocitinib) Cream

ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.34

ANZUPGO is approved in the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea, and the United Arab Emirates for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. ANZUPGO cream is also under investigation in other markets.

ANZUPGO® (delgocitinib) cream is also FDA approved in the U.S. for moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.35

Pleaseclick herefor full U.S. Prescribing Information, including Patient Information and Instructions for Use. 

In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights.

References

  1. Molin S, Baselga E, Navarro-Triviño FJ, et al. The DELTA TEEN Phase 3 trial: Efficacy and Safety of Delgocitinib Cream in Adolescents with Moderate to Severe Chronic Hand Eczema. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. Late Breaking News Session. D2T01.
  2. Bissonnette R, Agner T, Giménez-Arnau AM, et al. Safety of delgocitinib cream in adult patients with moderate to severe CHE: pooled analysis of five phase 2b and phase 3 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. Late Breaking News Session. D2T01.
  3. Bissonnette R, Kim BS, Peris K, et al. Delgocitinib cream improves pain and health-related quality of life in patients with CHE with severe pain. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. E-poster Presentation. P0358.
  4. Armstrong A, Bewley A, Wollenberg A, et al. Matching-Adjusted Indirect Comparison of the Efficacy at week 12 of Delgocitinib and topical PUVA in the treatment of Severe CHE. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. E-poster Presentation. P2798.
  5. Agner T, Aytan-Aktug D, Greig J, et al. Treatment with delgocitinib cream is associated with a reduction of Staphylococcus aureus density and pain in patients with mild to severe CHE. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. E-poster with a Short Oral Presentation. EPS03.
  6. Schuttelaar ML, Viard P, Kehlet C, et al. CHE has a Profound Impact on Daily Life, Social Interactions and Emotional Wellbeing: Results from a Global Patient Survey. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. E-poster Presentation. P2800.
  7. Fargnoli MC, Molin S, Bewley A, et al. Aetiological subtypes of moderate to severe CHE: Signs, symptoms and localisations -Results from the RWEAL study. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. E-poster Presentation. P0627.
  8. Halioua B, Berchi C, Pertus D, et Al. Burden of CHE in France Using the French Nationwide Claims Database. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. E-poster Presentation. P3280.
  9. Armstrong A, Sawad AB, Hazra N, et al. Patient perspectives in moderate-to-severe CHE: Understanding patient experience and factors influencing treatment preference through in-depth qualitative patient interviews in the US. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. E-poster Presentation. P0284.
  10. Armstrong A, et al. “Super-response” following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe Chronic Hand Eczema. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. ePoster Presentation. P0312.
  11. Bissonnette R, et al. Patient reported outcome measures and symptom improvements across subtypes of Chronic Hand Eczema: outcomes from the Phase 3 DELTA-1 and DELTA-2 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. ePoster Presentation. P0311.
  12. Stein Gold L, et al. Delgocitinib cream is well tolerated in Chronic Hand Eczema: DELTA 1 and 2 pooled analysis. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. ePoster Presentation. P0306.
  13. Eichenfield LF, et al. Delgocitinib cream 20 mg/g in Chronic Hand Eczema patients with skin fissures: efficacy, safety, and pharmacokinetics. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. ePoster Presentation. P0308.
  14. Mohandas P, et al. Clinical trial exit interviews in patients with moderate to severe Chronic Hand Eczema: evaluation of treatment experiences with delgocitinib cream 20 mg/g in the phase 3 DELTA 1 trial (no. 1455). Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. ePoster Presentation. P0280.
  15. Yu J, et al. Delgocitinib cream provides early and meaningful responses in adults with moderate to severe Chronic Hand Eczema: a pooled analysis of the phase 3 DELTA-1 and DELTA-2 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20  September. ePoster Presentation. P0307.
  16. Bunick C, et al. Delgocitinib cream formulation development for Chronic Hand Eczema (CHE): insights from patient preference and skin penetration studies. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. ePoster Presentation. P0309.
  17. Ehst B, et al. Delgocitinib cream leads to significant improvements across all Chronic Hand Eczema signs and region HECSI subscores in the phase 3 DELTA-1 and DELTA-2 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17-20 September. ePoster Presentation. P0310.
  18. ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN). Identifier: NCT05355818. https://clinicaltrials.gov/study/NCT05355818.
  19. ClinicalTrials.gov. National Library of Medicine (U.S.). Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/?g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema. Identifier: NCT03683719. https://clinicaltrials.gov/study/NCT03683719.
  20. ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1). Identifier: NCT04871711. https://clinicaltrials.gov/study/NCT04871711.
  21. ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2). Identifier: NCT04872101. https://clinicaltrials.gov/ct2/show/NCT04872101.
  22. Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461-473.
  23. ClinicalTrials.gov. National Library of Medicine (U.S.). Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (DELTA3). Identifier: NCT04949841 https://clinicaltrials.gov/ct2/show/NCT04949841.
  24. ClinicalTrials.gov. National Library of Medicine (U.S.). A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema. Identifier: NCT05259722. https://clinicaltrials.gov/study/NCT05259722.
  25. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg . 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360.
  26. Diepgen TL, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015 Jan;13(1):e1–22.
  27. Bissonnette R, et al. Redefining treatment options in chronic hand eczema (CHE). JEADV. 2010;24;1–20.
  28. Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3
  29. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378.
  30. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706.
  31. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991.
  32. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168.
  33. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626.
  34. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233.
  35. ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025.

 MAT-85579 September 2025

Kontakt:

Jeppe Ilkjær tlf.: +45 3050 2014 email: JEILK@leo-pharma.com

Jes Broe Frederiksen tlf.: +45 5360 5948 email: jebfe@leo-pharma.com

Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/release/14585362?publisherId=12353927&lang=da

** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **

-

København, 28/09/2025 - 08:00

Fakta: Skuespiller og sanger Jesper Groth

* Jesper Groth er 36 år gammel.

* Han er født på Ærø syd for Fyn.

* Jesper Groth er skuespiller uddannet fra Statens Teaterskole i København i 2015.

* Derudover er han musiker og komiker.

* Han udgør halvdelen af popduoen Fyr & Flamme, som vandt det danske melodigrandprix i 2021.

* Af den årsag deltog de samme år i den internationale melodigrandprix, Eurovision, hvor de dog ikke kvalificerede sig til den grande finale.

* Udover "Sygeplejeskolen" har Jesper Groth blandt andet haft roller i de danske film "Journal 64" og "Retfærdighedens ryttere".

/ritzau/

Læs Mere >>

København, 28/09/2025 - 08:00

TV 2-stjerne: Mit liv forandrer sig hvert syvende år

Martin Sylvest/Ritzau Scanpix/Arkivfoto/Ritzau Scanpix

Skuespiller Jesper Groth er mest til det vante og hjemlige. Sygeplejeskolen-stjernen har derfor heller ingen drømme om at slå igennem uden for landets grænser.

Ude er fint, men hjemme er allerbedst for skuespiller Jesper Groth.

Den 36-årige Sygeplejeskolen-stjerne er ikke bange for det ukendte, men det er bestemt heller ikke noget, han søger bare for at få spændingen.

- Jeg har altid troet, at jeg var en eventyrer, men jeg ville aldrig gøre som Bjørn, siger han.

Bjørn har været Jesper Groths karakter i TV 2 Charlie-serien siden første sæson.

Han rejste i seneste sæson til udlandet for at gå på en anden uddannelse, men han vendte hurtigt tilbage til Danmark.

Jesper Groth selv har altid en begrænsning på, hvor mange dage han vil være uden for landets grænser.

- Hver gang jeg har rejst, har jeg haft et maksimum på 17 dage, og så er jeg klar til at rejse hjem til Danmark og spise en tomatmad og drikke vand fra hanen.

Det kunne aldrig falde Jesper Groth ind at forlade den danske sommer.

- Jeg kan lide det lunefulde i, at det regner, og at det så bliver sol dagen efter. Havemøbler ud og ind og lyse nætter. Jeg er på mange måder meget dansk - også skuespilmæssigt, siger han og fortsætter:

- Jeg har ingen drømme om udlandet, og når jeg beskæftiger mig med satire, tager jeg udgangspunkt i det danske folk.

Selv om Jesper Groth ikke er decideret bange for det ukendte, dukkede der alligevel for nogle år siden en verdensomspændende virus op, som fik skuespilleren til at trække følehornene til sig.

- Jeg prøvede at blive ekstremt bange under corona. Jeg endte på en tropisk ø, der var så fjern, at man skulle svømme det sidste stykke vej med bagagen.

Mens Jesper Groth befandt sig på den cambodjanske ø, lukkede Danmark ned.

- Jeg vidste ikke, hvad corona var, så jeg troede, det var så alvorligt, at jeg ikke ville kunne komme hjem. Jeg blev så bange, at jeg tog hjem før tid.

Hans kammerat var stik modsat og blev siddende nede på stranden med en fadøl, imens Jesper Groth tog mod lufthavnen i sin søgen efter det velkendte.

- Strømmen gik hver dag, og der var intet hospital. Jeg gik mildt sagt i panik, og jeg var ikke tryg, før jeg så et fly, hvor der stod SAS på halefinnen.

Når han ser tilbage, kunne han godt være blevet siddende på stranden med tæerne i sandet.

Men at han ikke kendte noget som helst til corona gjorde, at han ville hjem til Danmark.

Det sker cirka hvert syende år, at der kommer noget uventet og livsforandrende ind fra højre i Jesper Groths liv, fortæller han.

- Jeg kom ind på teaterskolen, jeg er rykket til København, og jeg har mødt mennesker, der har åbnet døre i mit liv, siger skuespilleren.

Nu er der snart gået syv år siden seneste gamechanger, og Jesper Groth spekulerer i, om boligsituationen kan være den næste.

- Måske skal jeg for første gang prøve at bo alene, tænker han højt.

- Jeg har boet i kollektiv i 10-15 år. Det elsker jeg stadig, men jeg har også fået større lyst til plads, og jeg kan mærke på mine jævnaldrende, at det er noget, der sker.

Jesper Groth har egentlig pladsen i sit fritidshus på Ærø, hvor han kommer fra, men han kunne godt tænke sig at få mere jord under neglene i København end det, han får i altankassen.

- Jeg er glad for haver og blomster. Det kræver også noget plads. Jeg gider ikke kun at have en cykel i et cykelskur og ikke plads til noget andet.

Jesper Groths karakter i "Sygeplejeskolen", Bjørn, er nu også vendt hjem fra udlandet. Han og hans medstuderende kan følges søndag på TV 2 Charlie og TV 2 Play.

/ritzau/

Læs Mere >>

, 28/09/2025 - 10:00

FAKTA: Hvad kan du plante i oktober

* Oktober er optimal til plantning af barrodsplanter. Det kan både være træer, buske og roser. Dem kan du plante hele vinteren igennem, så længe jorden ikke er frossen. 

* Måneden er også god til at sætte hvidløg, så de er klar til høst næste år i juli. Du skiller hvidløget ad og planter feddene. Gå efter danskproducerede hvidløg, så får du dem, der er bedst egnet til klimaet herhjemme.

* Du kan også plante såkaldte kuldekimere. Det er for eksempel stauder, men også køkkenurter som kruspersille. Hvis de sås til efteråret, får de naturlig frost og tø hen over vinteren, og så spirer de til foråret.

Kilde: havefaglig rådgiver ved Haveselskabet Anne Stine Bruun.

/ritzau fokus/

Læs Mere >>

, 28/09/2025 - 10:00

Lille indsats i haven nu giver mindre ukrudt og bedre jord til foråret

Liselotte Sabroe/Ritzau Scanpix

Oktober er det ideelle tidspunkt at samle blade og bruge dem i komposten. Og det arbejde, du lægger nu, får du igen til foråret, lyder det fra haveeksperter.

Oktober er måneden, hvor haven langsomt lægger sig til ro under et tæppe af farverige blade.

Selv om det kan friste at rive dem væk og smide dem ud, gemmer bladene på en guldgrube af næring, der kan give næste års planter en god start, siger havefaglig rådgiver ved Haveselskabet Anne Stine Bruun.

- Hvis du vil forberede haven til næste år, så gælder det om at få noget organisk materiale ud på din jord, så der er næring til jordens organismer, og et højere indhold af humus er med til at holde på fugtigheden i jorden, forklarer hun.

Du kan rive bladene på græsplænen sammen og lægge dem ind i bedene.

- Sørg generelt for, at der ingen bar jord er. Det skal være dækket med planter eller dødt materiale for at beskytte mod frost og fordampning, siger Anne Stine Bruun.

Samme budskab lyder fra Eva Lyngesen, der er anlægsgartner og lærer på Jordbrugets UddannelsesCenter.

- Har du en køkkenhave, er det oplagt at få den gjort vinterklar, hvis du ikke dyrker vinterafgrøder, siger hun og fortsætter:

- Det kan du gøre ved at dække den med kompost, men det er også virkelig dejligt at genbruge blade til at dække den bare jord i køkkenhaven.

Inden du dækker til med kompost, anbefaler Eva Lyngesen desuden, at du får luget det sidste ukrudt i dine bede.

- Det mindsker ukrudtstrykket næste år, og samtidig gøder du dine planter, du holder fugtigheden og forbedrer jordstrukturen samt gavner mikroliv. Så er du foran til foråret, hvor det hele går løs, lyder det.

Du kan også bruge en eftermiddag på at få høstet de sidste æbler og pærer eller andre frugter og give dig tid til at henkoge og sylte.

- Det er jo en dejlig indendørs del af havearbejdet, når det begynder at ruske lidt mere udenfor, siger anlægsgartneren.

Har du drivhus, er oktober også ved at være sidste udkald for at få høstet tomater, fortæller Anne Stine Bruun fra Haveselskabet.

- Planterne er nok så småt begyndt at hænge, fordi det er for koldt for dem. De tåler nemlig ikke frost, uddyber hun.

Det samme gør sig gældende for dahlia, også kendt som georginer, lyder det fra den havefaglige rådgiver.

- De skal graves op af jorden, når den første frostnat har været der. Det er som regel lige efter efterårsferien, siger Anne Stine Bruun.

Og så kan du også bruge lidt tid på at overveje, hvordan haven skal se ud til vinter, siger Eva Lyngesen.

- Det kan være, at du vil have en stedsegrøn plante, du kan nyde i vinterhalvåret, eller at du vil have sat noget lys eller et fuglebræt op, foreslår hun og fortsætter:

- Sæt dig ned, kig ud på haven, og forestil dig, hvad du gerne vil se på til vinter, hvor haverne nogle gange bliver lidt tomme.

/ritzau fokus/

Læs Mere >>

TjekDet - faktatjek

Ni.dk er et manuelt indekseret linkkatalog, der leverer den bedste indgang til den danske del af internettet. Når du søger information om et givent emne, præsenterer Ni.dk de bedste hjemmesider på en nem og overskuelig måde